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Abstract
Background: Pulmonary surfactant protein D (SP-D) is considered as a candidate biomarker for the functional
integrity of the lung and for disease progression, which can be detected in serum. The origin of SP-D in serum
and how serum concentrations are related to pulmonary concentrations under inflammatory conditions is still
unclear.
Methods: In a cross-sectional study comprising non-smokers (n = 10), young - (n = 10), elderly smokers (n = 20),
and smokers with COPD (n = 20) we simultaneously analysed pulmonary and serum SP-D levels with regard to
pulmonary function, exercise, repeatability and its quaternary structure by native gel electrophoresis. Statistical
comparisons were conducted by ANOVA and post-hoc testing for multiple comparisons; repeatability was assessed
by Bland-Altman analysis.
Results: In COPD, median (IQR) pulmonary SP-D levels were lower (129(68) ng/ml) compared to smokers (young:
299(190), elderly: 296(158) ng/ml; p < 0.01) and non-smokers (967(708) ng/ml; p < 0.001). The opposite was
observed in serum, with higher concentrations in COPD (140(89) ng/ml) as compared to non-smokers (76(47) ng/
ml; p < 0.01). SP-D levels were reproducible and correlated with the degree of airway obstruction in all smokers. In
addition, smoking lead to disruption of the quaternary structure.
Conclusions: Pulmonary and serum SP-D levels are stable markers influenced by smoking and related to airflow
obstruction and disease state. Smaller subunits of pulmonary SP-D and the rapid increase of serum SP-D levels in
COPD due to exercise support the translocation hypothesis and its use as a COPD biomarker.
Trial registration: no interventional trial
Introduction
Chronic obstructive pulmonary diseases (COPD) is a
multi-component disease. It is characterized by airflow
limitation that is not fully reversible when treated with
bronchodilators. In COPD an abnormal airway inflam-
matory response, a thickening of airway walls, destruc-
tion of alveoli and the enlargement of air spaces can be
observed [1]. Tobacco smoking is the primary cause and
major risk factor for the development of COPD and in
most industrialized countries the disease has an increas-
ing prevalence [2].
SP-D is synthesized in type II pneumocytes and Clara
cells. It is composed of monomers (43 kDa), which
assemble into trimers via disulfid crosslinking and
undergo further multimerization to higher order such as
dodecamers and oligomers (~ 1 MDa) [3]. Each mono-
mer has four distinct domains: the carbohydrate recog-
nition domain (CRD), the neck domain, a collagenous
domain and the N-terminal cystein-rich domain. The
integrity of the quaternary structure is important for
functions such as in pulmonary surfactant and lipid
homeostasis [4], innate immunity [3], regulation of cel-
lular clearance as well as inflammatory and immune
responses [5]. Importantly, destruction of the quaternary
structure leads to reduced binding affinity of the CRD
to pathogens or allergens [6,7] and can promote a
switch towards pro-inflammatory signalling [8,9].
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levels have been reported for lung diseases such as pul-
monary alveolar proteinosis, cystic fibrosis, COPD, and
for infectious diseases like tuberculosis and bacterial
pneumonia [10-12]. Lomas et al. also report an associa-
tion between high serum SP-D levels and an increased
risk for COPD exacerbations [12]. These data suggest
that SP-D levels in serum reflect disease activity and SP-
D has therefore been suggested as a potential biomarker
for the epithelial integrity in COPD.
The precise mechanism leading to increased serum
levels is unclear. Based on the currently most widely
accepted hypothesis, SP-D translocates from the lung
into the blood, a process that could be regulated by
changes in the alveolar-capillary permeability [13]. How-
ever, the relationship between concentrations in serum
and bronchoalveolar lavage fluid (BAL) is different for
allergic diseases like asthma and for smokers or patients
with COPD. In asthma or allergen induced airway
inflammation increased levels of SP-D were detected in
both BAL [14] and serum [15], compatible with the
notion that a higher concentration in one compartment
also leads to a higher concentration in the other. For
smokers and especially for COPD patients reduced levels
of SP-D were detected in BAL, however, both groups also
show elevated concentrations of SP-D in serum [12]. In
line with this, higher levels of SP-D were observed in
BAL of patients under steroid treatment [16], while treat-
ment with oral steroids leads to a decline in serum to SP-
D concentrations of COPD patients [12].
However, despite these advances, the utility of SP-D as
a biomarker has not yet been fully realized due to sev-
eral factors: 1) A complete characterization of SP-D
expression in both compartments (BAL and serum)
from healthy controls, smokers or COPD patients has
been lacking; 2) Oxidative-nitrative stress and the action
of proteases are both increased in smokers and COPD
patients [1] and have been shown to modify the qua-
ternary structure of SP-D [17,18] thus potentially affect-
ing accurate measurement; 3) Although SP-D was
shown to be unaffected by physical exercise in healthy
volunteers [19], the effect on exercise on these para-
meters in disease states is largely unknown.
Based on this we embarked on a comprehensive charac-
terization of SP-D expression in controls, smokers and
patients with COPD. We hypothesized that due to changes
in barrier integrity and molecular sizing, lower SP-D levels
in BAL would be associated with higher concentrations of
SP-D in serum in smokers and especially in COPD
patients. In addition to assessment of the overall concen-
tration of SP-D in two compartments, we also assessed the
quaternary structure of SP-D in BAL samples and mea-
sured SP-D levels in serum samples obtained before, dur-
ing and after a moderate exercise period.
Materials and methods
Study subjects
Peripheral blood and BAL was investigated from sub-
jects of two different studies. Both studies were per-
formed in accordance with Good Clinical Practice and
the Declaration of Helsinki. Subjects gave their written
consent after being fully informed about the purpose
and nature of the study. The studies were approved by
the Ethical Committee of Hannover Medical School.
Study in healthy non-smokers (H) and young smokers (S1)
Ten non-smokers (21 - 36 years, 3 male) and ten smokers
(21 - 49 years, 7 male) with no history of allergic or other
diseases were enrolled into the study. Only subjects with
forced expiratory volume in 1 sec (FEV1)>7 7 %o fp r e -
dicted normal and a ratio of FEV1/forced vital capacity
(FVC) > 70%, normal findings in electrocardiogram, differ-
ential blood cell count, blood coagulation, and serum
parameters (gamma-glutamyl-transferase, aspartate ami-
notrans-ferase, alanine aminotransferase, urea, creatinine,
sodium, potassium, IgE) as well as negative skin-prick test
for 15 standard allergens (ALK-SCHERAX Arzneimittel
GmbH, Hamburg, Germany) were included. None of the
subjects suffered from an acute bronchitis 4 weeks prior to
bronchoscopy. Non-smokers were required not to have
smoked for at least five years. An inclusion criterion for
smokers was a minimum consumption of 15 cigarettes per
day for at least two years. Levels of cotinine were mea-
sured to prove presence or absence of nicotine exposure.
After a screening visit, blood sampling and broncho-
s c o p yw i t hB A Lw a sp e r f o r m e dd u r i n gas i n g l ev i s i t .
Subjects were discharged from the study following a ter-
mination visit 1 - 7 days after the procedures.
Study in elderly smokers (S2) and smokers with COPD (C)
Forty current smokers (40 - 75 years) with at least 10 pack
years and active smoking confirmed by urine cotinine
measurement were enrolled. One half of the group (n =
20) had normal pulmonary function (FEV1/FVC ≥ 70%
and FEV1 ≥ 85% pred.) while the other subjects (n = 20)
had COPD GOLD stage 2 (Global Initiative for Chronic
Obstructive Lung Disease) with typical clinical characteris-
tics (cough and sputum) and with a post-bronchodilator
FEV1/FVC < 67% and 50% ≤ FEV1< 75%. The groups were
matched for age and gender (6 female/14 male) and no
subject suffered from a respiratory tract infection or recent
exacerbation of COPD (within 4 weeks prior to screening
examination). None of the subjects had a history or evi-
dence of clinically relevant allergies, evidence of any dis-
ease that would have affected the subject’s safety during
study participation, particularly during bronchoscopy and
exercise testing including pulmonary, hepatic, renal (crea-
tinine above 2 mg/dL), gastrointestinal, haematological,
endocrinological, metabolic, neurological, psychiatric,
or cardiovascular disorders, particularly arterial hyper-
or hypotension, symptomatic coronary heart disease
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congestive heart failure (New York Heart Association
functional classification III and IV), and cardiac arrhyth-
mia. Furthermore, subjects with chronic inflammatory dis-
ease other than COPD, diagnosis of cancer within 5 years
of study start, evidence of drug or alcohol abuse, or regular
intake of theophylline, lipoxygenase inhibitors, leukotriene
antagonists, inhaled and oral cromones, systemic gluco-
corticosteroids, inhaled and topical glucocorticosteroids,
anti-TNF-a agents, hormonal contraceptives, and nitrates
were not eligible for participation.
The study was composed of two pairs of consecutive
v i s i t s :v i s i t1a n d2f o l l o w e d2 8±5d a y sl a t e rb yv i s i t3
and 4. Visit 2 and visit 4 was performed 3 to 7 days
after visit 1 and visit 3, respectively. Bronchoscopy and
blood sampling was performed on visit 2 and 4, serum
sampling during constant load exercise was performed
on visit 1 and 3. Lung function measurements were per-
formed at screening prior to visit 1. A termination visit
with discharge of the subject from the study was per-
formed 1 - 4 days after visit 4.
Exercise
Subjects with COPD and elderly smokers first per-
formed a screening exercise test to determine the peak
work capacity. After a one minute warm-up consisting
of load less pedalling, a stepwise increase in the work
rate of 10 watts every minute, starting at 10 watts fol-
lowed. Pedalling rates were kept within 50-70 rpm
throughout exercise. Exercise continued until the subject
felt tired, was unable to maintain a pedalling frequency
of at least 40 rpm, or if exercise could not be continued
safely. Peak work capacity (Wpeak)w a sd e f i n e da st h e
highest work rate that could be maintained for at least
30 seconds. The constant load exercise test was con-
ducted at the indicated time points. After warm up, the
work rate was increased to 75% of Wpeak. The subject
was encouraged to exercise for as long as possible, but
the maximum time was limited to 30 minutes.
Bronchoscopic procedure and processing BAL cells
The bronchoscopic procedure and the processing of BAL
fluid and cells was performed as described before [20].
Briefly, fiberoptic bronchoscopy was done with standard
premedication under topical anesthesia to allow collec-
tion of BAL (5 × 20 mL of sterile saline plus initial 20 mL
discard). BAL cells were filtered through a 100-μmf i l t e r ,
centrifuged at 250 g for 10 min, and resuspended in
phosphate-buffered saline (PBS). The total count of
nucleated cells was performed using a Neubauer hemo-
cytometer. Differential cell counts were performed from
cytospin slides, with 300 cells per slide being counted.
Protein content in BAL and serum was determined
according to the method of Bradford [21].
Serum sampling
Blood was collected in a S-Monovette
®; (Sarstedt,
Nuembrecht, Germany), allowed to stand for 30 min,
and then centrifuged for 15 min with 1600 × g. Serum
was aliquoted and kept frozen at -80°C until analysis.
Reagents
All reagents for electrophoresis and immunoblotting
were purchased from Invitrogen, Carlsbad, CA, USA
unless otherwise specified.
Anti SP-D antibody (Ab #3434) was purchased from
Chemicon, Temecula, CA, USA and a polyclonal anti-
body against SP-D (Ab 1754) was produced as pre-
viously described [22].
Measurement of surfactant protein D in BAL and serum
SP-D levels in serum and BAL samples were measured
with a colorimetric sandwich assay in duplicates (Bio-
Vendor, Heidelberg, Germany) according to the manu-
facturer’s instruction.
Polyacrylamide Gel Electrophoresis and Immunoblotting
for SP-D
BAL proteins were separated and analyzed by denaturating
SDS PAGE and immunoblotting as described before [22].
Native gel electrophoresis for detection of the qua-
ternary SP-D structure was performed according to
Schagger [23] using NativePAGE 4-16% Bis-Tris gels.
Briefly, equal amounts of SP-D (as determined using
SDS PAGE) were mixed with cold native sample buffer
before loading. Electrophoresis was run at room tem-
perature at a constant voltage of 150 V for 2 h. Immu-
noblotting and detection of SP-D was performed as
described above.
Oxidative modification of SP-D in vitro
Recombinant rat SP-D was produced in CHO cells as
described previously [24]. For in vitro oxidative modifi-
cation of rrSP-D (10 μg/ml) and BAL proteins, incuba-
tion with the synthetic oxidizing agent AAPH (2,2-Azo-
bis-(2-amidinopropane)-dihydrochloride, Sigma, Tauf-
kirchen, Germany) 74 mM for 2 h at 37°C was per-
formed as described before [18]. Modifications were
analyzed by blue native gel electrophoresis.
Statistical analysis
Statistical analysis was performed by SAS (Cary, NC,
USA) and Statistica (Statsoft, Hamburg, Germany).
Comparisons between subject groups of clinical data
and SP-D levels were conducted by ANOVA and post
hoc testing for multiple comparison with Newman-
Keuls (Table 1 and 2) and Tukey-Kramer (Figure 1),
respectively. Analysis was performed after log-transfor-
mation for non-normal distributed data. Repeatability
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lation coefficients were derived from one-way ANOVA
as the ratio of variance among subjects to total variance
(Figure 2). Correlations were conducted by linear regres-
sion analysis according to Spearman (Figure 3). Values
are given as mean ± SEM or median and quartiles,
depending on data distribution. A p-value < 0.05 was
considered as statistically significant.
Results
Basic data and clinical characteristics
Basic data and clinical characteristics of the study sub-
jects are given in Table 1. In smokers with COPD, lung
function was lowest and pack years were highest com-
pared to all other groups. The two groups of smokers
(S1 and S2) had similar lung function, but elderly smo-
kers had more pack years compared to young smokers.
Patients with COPD and elderly smokers were matched
for gender, while females dominated in the healthy non-
smoking group and males were more prevalent in the
group of young smokers.
BAL recovery and differential cell count
As shown in Table 2, BAL fluid recovery was signifi-
cantly reduced in patients with COPD. Cell numbers
p e rm LB A Lw e r ef o u n de l e v a t e di na l ls m o k e r sc o m -
pared to healthy non-smokers, which was due to an ele-
vation of the macrophage population. In young smokers
neutrophils were found to be significantly increased
compared to non-smokers. In patients with COPD, the
number of lymphocytes was significantly reduced. No
significant differences in total and differential cell count
were seen between young smokers and elderly smokers.
SP-D levels in BAL and serum
Total protein levels in BAL were not significantly differ-
ent between groups (H: 74.1 ± 12.3 μg/ml, S1: 84.3 ± 12.2
μg/ml, S2: 78.1 ± 8.6 μg/ml, and C: 65.6 ± 5.6 μg/ml).
In contrast, SP-D levels in BAL were decreased in
smokers and patients with COPD (Figure 1A).
While healthy, non-smokers had a median (quartiles)
SP-D level in BAL of 967 (691;1399) ng/ml, SP-D was
significantly reduced in BAL of young and elderly smo-
kers (S1: 299 (205;395), p < 0.001; S2: 296 (213;371) ng/
ml, p < 0.001) with no difference between these two.
Importantly, SP-D levels in BAL of patients with COPD
were lowest (129 (101;169) ng/ml, p < 0.001) giving a
7.5 fold reduction compared to healthy, non smoking
subjects (H).
SP-D levels in serum (Figure 1B) showed an inverse
relation between groups compared to BAL. While
healthy subjects had the lowest SP-D levels in serum (76
(48;95) ng/ml) they were significantly elevated in smo-
kers with COPD (140 (104;193) ng/ml, p < 0.01). No
differences in SP-D serum levels between young smo-
kers (S1) and elderly smokers (S2) were observed (88
(74;119) vs. 85 (71;123) ng/ml). In Figure 1C the ratio of
SP-D in BAL and serum is shown. This ratio was signifi-
cantly decreased in patients with COPD compared to
healthy controls (median (quartiles): 0.8 (0.5;1.9) versus
11.6 (10.0;21.5), p < 0.001). The ratio in COPD patients
was lower compared to smokers without lung function
impairment.
Reproducibility of SP-D levels in serum and BAL
To assess the potential of SP-D as a biomarker for
COPD we tested the reproducibility of SP-D levels in
Table 1 Clinical characteristics
subjects age gender FEV1
[% predicted]
FEV1/FVC
[%]
Pack years
healthy non-smokers (n = 10) 25.8 ± 1.4
# 7 F, 3 M 106.1 ± 3.0
# 79.8 ± 2.1
# 0
#
young smokers (n = 10) 30.7 ± 2.9
# 3 M, 7 F 97.8 ± 3.9
# 78.8 ± 2.0
# 14.9 ± 4.4
#.
elderly smokers (n = 20) 52.8 ± 1.4* 14 M, 6 F 112.8 ± 3.3
# 74.7 ± 1.0
# 38.6 ± 5.5*
smokers with COPD (n = 20) 55.0 ± 1.4* 14 M, 6 F 60.5 ± 1.5* 46.9 ± 2.2* 48.0 ± 2.7*
(F = female, M = male, FEV1 = forced expiratory volume in one second, FVC = forced vital capacity. Mean values ± SEM are given. *indicates p < 0.05 compared
to healthy non-smokers and # indicates p < 0.05 to smokers with COPD).
Table 2 Bronchoalveolar lavage data
Group Recovery Total Cells Macrophages Neutrophils Eosinophils Lymphocytes
(ml) (×10
3/ml) (×10
3/ml) (%) (×10
3/ml) (%) (×10
3/ml) (%) (×10
3/ml) (%)
H 75.0 ± 3.1 65.7 ± 5.5 58.7 ± 5.1 89.5 ± 0.9 1.4 ± 0.2 2.2 ± 0.3 0.4 ± 0.2 0.6 ± 0.3 4.8 ± 0.7 7.4 ± 1.1
S1 73.8 ± 3.2 220.1 ± 54.7* 197.3 ± 48.7* 89.8 ± 0.7 8.6 ± 2.4
# 4.1 ± 0.7
# 3.8 ± 2.6 1.1 ± 0.5 9.0 ± 1.8
# 4.2 ± 0.2
#
S2 68.3 ± 3.1 240.5 ± 33.7* 220.1 ± 31.7* 94.8 ± 0.7 3.1 ± 1.0 1.3 ± 0.4 1.2 ± 0.4 0.5 ± 0.1 3.3 ± 1.0 1.2 ± 0.2
#
C 43.7 ± 3.7
# 232.5 ± 37.4* 224.5 ± 29.2* 90.3 ± 4.5 2.0 ± 0.4 1.3 ± 0.5 2.0 ± 0.9 0.8 ± 0.3 1.9 ± 0.7* 0.7 ± 0.2
#
Fluid recovery and cell counts (absolute and percentage of cells) in bronchoalveolar lavage of healthy, non smoking subjects (H) young smokers (S1), elderly
smokers (S2) and smokers with COPD (C). Values are given as means ± SEM; *indicate p < 0.05 and
#p < 0.01 compared to healthy non-smokers (H).
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prising elderly smokers (S2, n = 20) and smokers with
COPD (C, n = 20) (Figure 2). The mean time period
between measurements was 32 ± 10 days.
The reproducibility was better for SP-D levels in
s e r u m( F i g u r e2 B )c o m p a r e dt oB A L( F i g u r e2 A ) .T h e
correlation coefficient was r = 0.76 for serum and r =
0.65 for BAL (both p < 0.001).
SP-D ratio correlates to lung function in smoking subjects
A correlation of serum and BAL SP-D levels with the
FEV1 (% pred.) of smoking subjects (S1, S2, C) was
Figure 1 SP-D levels in BAL and Serum. SP-D levels in BAL (A) serum (B) and the ratio of BAL/serum SP-D levels (C) of healthy, non-smoking
subjects (H, open squares n = 10), young smokers (S1, black squares, n = 10), elderly smokers (S2, open triangles, n = 20) and smokers with
COPD (C, black triangles n = 20). Log-transformed individual data points are provided together with the respective mean of the log transformed
data. Values are displayed on a logarithmic scale. *p < 0.05, **p < 0.01, ***p < 0.001 compared to H,
#p < 0.05,
##p < 0.01 compared to C.
Figure 2 Repeatability of SP-D measurements. Bland-Altman plot to assess the repeatability of SP-D levels in BAL (A) and serum (B) of elderly
smokers (S2) and smokers with COPD between two samplings with a time delay of about 34 ± 10 days. The coefficient of reliability (derived
from one-way ANOVA as the ratio of variance among subjects to total variance) is given as intraclass correlation coefficient (ICC).
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0.006). In addition, there was a correlation of serum
(r = -0.35, p = 0.013) and BAL SP-D levels (r = 0.62,
p < 0.0001) with the degree of airway obstruction
(FEV1/FVC) within the group of smokers (S1, S2, C, n =
50, Figure 3A, B) and in line with this a significant posi-
tive correlation was observed for the BAL/serum ratio
(r = 0.60, p < 0.001). Consequently, the BAL/serum SP-
D ratio declined with the worsening in lung function
Figure 3C).
Exercise-induced alterations of serum SP-D levels
We measured SP-D levels in serum during constant load
exercise in elderly smokers (S2, n = 15) and smokers
with COPD (C, n = 15) (Figure 4). In line with the find-
ings under resting conditions, SP-D levels in serum of
elderly smokers were significantly lower during exercise
compared to patients with COPD (p < 0.001). Interest-
ingly, we observed a significant increase change in
serum SP-D levels as early as 5 min after the start of
the exercise in patients with COPD (p < 0.05). A com-
parable change was also observed in the group of smo-
kers, although to a later time point. When the exercise
test was repeated, a comparable kinetic of changes was
detected.
Smoking alters the quaternary structure of SP-D
In addition to the quantitative changes of SP-D levels in
the different compartments, its quaternary structure was
analysed in BAL of healthy controls, smokers and
patients with COPD (Figure 5A and 5B, bottom panels).
Separation under native conditions (Figure 5A lower
panel) did not show immunoreactive bands and there-
fore did not provide evidence for changes in the qua-
ternary structure of SP-D from healthy, non smoking
subjects (H). Note that intact SP-D is too large to
migrate into the gel. In contrast, lower molecular weight
SP-D bands could be detected in the SP-D of smoking
Figure 3 Correlation of lung function measurements and SP-D levels. Correlation of SP-D levels in BAL (A), serum (B) or the ratio of SP-D in
BAL and serum (C) with FEV1/FVC in smokers (n = 50, young and elderly smokers and smokers with COPD). FEV1: forced expiratory volume in
1 s, FVC: forced vital capacity. Correlations were significant with p < 0.001, r = 0.62 (A); p = 0.013, r = 0.-0.35 (B) and p < 0.001, r = 0.60 (C).
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possibly through the disruption of its quaternary struc-
ture towards smaller subunits.
Due to the much lower concentrations of SP-D levels
in BAL of patients with COPD compared to healthy
individuals (Figure 1A), samples were concentrated prior
to analysis by native electrophoresis and immunoblot-
ting. The quaternary structure of SP-D in smokers with
COPD was also found disrupted (Figure 5B), however,
due to the concentration process, the immunoblot
shown in Figure 5B is not comparable to protein band
intensities of S1 shown in Figure 5A.
Since increased amounts of reactive oxygen species
(ROS) are thought to be present in the lungs of smokers
(either derived from cigarette smoke itself or subse-
quently induced by inflammatory cells) we tested,
whether oxygen radicals can alter the structure of
recombinant rat SP-D (rrSP-D) and SP-D in BAL of a
healthy non-smoker (H) in vitro.A sd e m o n s t r a t e di n
Figure 6, the incubation with an oxygen radical donor
resulted in the disruption of the native structure of
rrSP-D into smaller subunits. SP-D from BAL of healthy
subjects also migrated into the gel after treatment with
the oxygen radical donor, indicating that smaller subu-
nits were present. However, the pattern of oxidized SP-
D in vitro did not exactly match the SP-D band pattern
found in smokers in vivo (S1, Figure 6) probably due to
differences in processes that occur in vitro and in vivo.
Discussion
Using samples simultaneously obtained from the two
major reservoirs of SP-D, the current study presents
new data demonstrating that pulmonary and serum SP-
D levels appear to be stably expressed in both patients
with COPD and controls, can be influenced by smoking,
and reflect the degree of airway obstruction and disease
s t a t e .T h eh i g h e s tp u l m o n a r ya n dt h el o w e s ts e r u mS P -
D concentrations were detected in healthy subjects.
Smoking reduced the level of SP-D in BAL and
increased the concentration in serum, apparently
Figure 4 Kinetics of SP-D levels in serum during constant load exercise. Kinetics of SP-D levels in serum during constant load exercise
taken at 4 different time points: at rest (rest), after 5 min of steady state exercise (5 min), at the end of loaded exercise (end), and 20 min after
exercise (recovery). Change in SP-D serum concentrations over time in elderly smokers (S2, open triangles, dashed line, n = 15) and smokers
with COPD (C, black triangles, n = 15) are shown. Data are given on the vertical axis on a logarithmic scale as mean ± SEM, * p < 0.05
compared to time point “rest”.
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kers with COPD, changes in BAL/serum SP-D ratio
were most pronounced and for the first time, within
minutes after the start of moderate exercise, an increase
in serum SP-D levels with a reproducible kinetic profile
w a so b s e r v e di ns m o k e r sa n di np a t i e n t sw i t hC O P D .
Finally, we found changes in the quaternary structure of
SP-D in these two groups suggesting a previously unap-
preciated smoking related effect. Together the data sup-
port the hypothesis for the translocation of SP-D from
airways to serum and underscore the importance of
concentration gradients, barrier integrity, and potentially
quaternary structure in influencing the quantitative
expression levels in these compartments.
The majority of SP-D production occurs in the lung
with spatial localization to type II pneumocytes and
Clara cells lining the distal airways [25]. The fact that
SP-D can also be detected in serum moved it into focus
as a potential biomarker [12,26]. SP-D has been analysed
in BAL and serum of different patient groups before,
however so far, only indirect evidence suggests lower
than normal values in BAL and higher than normal
values in serum of COPD patients [12,16]. Our data
show that the BAL/serum ratio is markedly changed in
COPD patients. In our present study we demonstrate
that drastic changes with respect to the BAL/serum
ratio are especially evident in COPD patients. Under the
conditions used in our study, the BAL/serum ratio was
about 10-fold higher in healthy subjects as compared to
COPD patients.
BAL fluid recovery from COPD patients is often
potentially more variable than healthy volunteers, as
indicated in Table 2. However, protein levels were not
statistically different between groups making it rather
unlikely that differences in BAL dilution are responsible
for the observed differences in BAL SP-D concentra-
tions. In addition, the measurement of SP-D in BAL
showed a decent reproducibility and was in a similar
range as described by Sims et al. [16]. The SP-D con-
centrations in serum showed an even better reproduci-
bility and were comparable to those reported by Lomas
et al. [12]. Furthermore, the stability of the BAL/serum
ratios over a time period of 4 weeks indicates that this
Figure 5 Quaternary structure of pulmonary SP-D.T h e
quaternary structure of SP-D in BAL: A) equal amounts of SP-D were
loaded as indicated by equal band intensities of the SP-D monomer
(43 kDa) in SDS page under reduced conditions and
immunoblotting (upper panel A and B). The quaternary structure of
SP-D in bronchoalveolar lavage from 4 healthy subjects (H) and
smokers (S1) is demonstrated by blue native electrophoresis and
immunoblotting (lower panel A) as well as for 3 smokers with
COPD (C) (lower panel B). Due to very low SP-D levels in BAL of
COPD subjects the displayed intensity of SP-D bands is not
comparable between A and B.
Figure 6 Oxidative induced disruption of the quaternary
structure of pulmonary SP-D. Blue native electrophoresis of
surfactant protein-D after incubation with an oxygen radical donor
(+). Disruption of the multimeric structure (*) can be chemically
induced by exposing rr-SP-D or BAL from healthy subjects to 74
mM of the oxidizing agent 2,2-Azo-bis-(2-amidinopropane)-
dihydrochloride (+).
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ease states.
In line with previous studies we found a weak but sig-
nificant correlation between SP-D levels in BAL and in
serum with the degree of airway obstruction [26]. Inter-
estingly our correlation confirm data from a recently
published study, where the ratio of SP-D in BAL and
serum was shown to correlate significantly with the
degree of airway obstruction in a trial with smoking
subjects [27]. These data are encouraging to use SP-D
as a biomarker/surrogate marker for clinical read outs
and would also justify larger validation trials.
The function of SP-D in serum if any as well as its
source is still unclear. Serum SP-D levels have been
shown to be steroid sensitive and to reflect an increased
risk for exacerbations in patients with COPD [12]. The
origin of serum SP-D is currently considered to be the
lung and raised serum levels have been related to
increased concentrations in the lung e.g. during allergic
inflammation [14], or have been suggested to be due to
an increased permeability of the lung and leakage from
the pulmonary site [12]. The changes in the BAL/serum
ratio observed in our study support the permeability
hypothesis. However, the reproducible rapid increase
during exercise in smokers and COPD patients in serum
SP-D concentrations would then require a similar rapid
change in alveolar/vascular permeability, which at least
in healthy subjects [28] has not been detected before.
The similar protein concentration in BAL fluid
between groups further suggest that the translocation of
molecules between serum and the lung is rather com-
plex. Our data does not solve this issue and it is impor-
tant to keep in mind that SP-D is not only expressed in
the lung and could therefore also be derived from other
extrapulmonary sources [29].
Beside alterations of SP-D levels, we found remarkable
changes in protein patterns after native separation and
immunoblotting indicating a loss of its multimeric
structure in smokers and smokers with COPD. The dis-
ruption of the multimeric structure of SP-D can have
several deleterious consequences regarding its function
in host defence and innate immunity [30], lowering the
binding affinity to pathogen ligands [7] and might also
reduce its anti-oxidant functions [6]. The loss of multi-
meric integrity towards smaller subunits might also play
a role in the hypothesized increased translocation of
pulmonary SP-D into the circulation because SP-D
molecules with lower molecular weight might more
easily translocate into the systemic circulation.
Although native gel electrophoresis does not allow a
prediction of the precise molecular weight of a protein, we
found SP-D fragments in BAL in a range of about 200-800
kDa, indicating that it was not completely disrupted to
monomers (43 kDa) but rather de-multimerized. Such
degradation products have not been observed or reported
so far, and it is tempting to speculate that oxidative and
nitrosative stress might be the causes to initiate disruption
by amino acid modification. Whether the appearance
of lower multimeric forms or the susceptibility to post-
tranlational modification by SNO, ONOO or crosslinking
of SP-D are affected by theD N Ap o l y m o r p h i s mT h r /
Thr
11 described by Leth-Larsen remains speculative, since
we did not analyse for polymorphisms [31]. Further, we
found smaller multimeric forms in smokers and signifi-
cantly increased SP-D serum levels, whereas Leth-Larsen
reported an reduction of SP-D serum levels associated
with Thr/Thr
11 genotypes.
Indeed, we found more nitrite in smoker compared to
non-smoker BAL and first evidence for more S-nitrosy-
lated SP-D (SNO-SP-D) in smokers (data not shown).
The formation of S-nitrosothiol occurs through reactive
nitrogen species and causes loss of multimerization and
additional pro-inflammatory signalling activity on
macrophages [9].
Radical oxygen species have also the potential to mod-
ify proteins, introducing carbonyl groups at certain
amino acids [32]. This modification can alter the qua-
ternary structure, and incre a s et h es u s c e p t i b i l i t yt o
further degradation by proteinases. ROS are elevated in
smokers [33], derived either directly from inhaled cigar-
ette smoke or are released in response to smoking from
various cells like neutrophils and macrophages. We
could show in vitro that the native structure of SP-D
c a nb em o d i f i e db ya no x i d a n tb u tw ew e r en o ta b l et o
detect carbonyl groups in BAL from smokers due to
methodical limitations. However, in cystic fibrosis these
oxidative modifications of SP-D have been observed and
they were associated with a loss of functional properties
i.e. a reduced agglutination of Pseudomonas aeruginosa
[18]. Increased bacterial and viral colonisation are
common in patients with COPD [34], which might be
linked to reduced pulmonary SP-D levels as well as to a
potentially impaired functionality due to the observed
disrupted structure [6]. To further elucidate the role of
SP-D structural modifications in COPD, a quantitative
evaluation between all groups with respect to the pro-
portions of disrupted relative to the total SP-D level
will be required, and there appears to be a need to clar-
ify if ELISA measurements are affected by these SP-D
modifications.
In conclusion, we showed that pulmonary and serum
SP-D levels are stable markers that are related to smok-
ing, airway obstruction, and disease state. In addition,
we demonstrated that cigarette smoke is capable to dis-
rupt SP-D’s quaternary structure, which might play a
role in an impaired immunological function and an
Winkler et al. Respiratory Research 2011, 12:29
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Page 9 of 11increased translocation of SP-D from the lung into the
circulation.
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